Azimi Iman, Stevenson Ralph J, Zhang Xuexin, Meizoso-Huesca Aldo, Xin Ping, Johnson Martin, Flanagan Jack U, Chalmers Silke B, Yoast Ryan E, Kapure Jeevak S, Ross Benjamin P, Vetter Irina, Ashton Mark R, Launikonis Bradley S, Denny William A, Trebak Mohamed, Monteith Gregory R
Division of Pharmacy, College of Health and Medicine, University of Tasmania, Hobart, Tasmania 7001, Australia.
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, 1142, New Zealand.
ACS Pharmacol Transl Sci. 2020 Feb 14;3(1):135-147. doi: 10.1021/acsptsci.9b00081. Epub 2020 Jan 13.
Store operated calcium (Ca) entry is an important homeostatic mechanism in cells, whereby the release of Ca from intracellular endoplasmic reticulum stores triggers the activation of a Ca influx pathway. Mediated by Orai1, this Ca influx has specific and essential roles in biological processes as diverse as lactation to immunity. Although pharmacological inhibitors of this Ca influx mechanism have helped to define the role of store operated Ca entry in many cellular events, the lack of isoform specific modulators and activators of Orai1 has limited our full understanding of these processes. Here we report the identification and synthesis of an Orai1 activity enhancer that concurrently potentiated Orai1 Ca -dependent inactivation (CDI). This unique enhancer of Orai1 had only a modest effect on Orai3 with weak inhibitory effects at high concentrations in intact MCF-7 breast cancer cells. The Orai1 enhancer heightened vascular smooth muscle cell migration induced by platelet-derived growth factor and the unique store operated Ca entry pathway present in skeletal muscle cells. These studies show that IA65 is an exemplar for the translation and development of Orai isoform selective agents. The ability of IA65 to activate CDI demonstrates that agents can be developed that can enhance Orai1-mediated Ca influx but avoid the cytotoxicity associated with sustained Orai1 activation. IA65 and/or future analogues with similar Orai1 and CDI activating properties could be fine tuners of physiological processes important in specific disease states, such as cellular migration and immune cell function.
储存性钙(Ca)内流是细胞中一种重要的稳态机制,通过该机制,细胞内内质网储存的Ca释放会触发Ca内流途径的激活。由Orai1介导,这种Ca内流在从泌乳到免疫等多种生物过程中具有特定且重要的作用。尽管这种Ca内流机制的药理学抑制剂有助于确定储存性Ca内流在许多细胞事件中的作用,但缺乏Orai1亚型特异性调节剂和激活剂限制了我们对这些过程的全面理解。在此,我们报告了一种Orai1活性增强剂的鉴定与合成,该增强剂同时增强了Orai1的钙依赖性失活(CDI)。这种独特的Orai1增强剂对Orai3的影响较小,在完整的MCF-7乳腺癌细胞中高浓度时具有微弱的抑制作用。Orai1增强剂增强了血小板衍生生长因子诱导的血管平滑肌细胞迁移以及骨骼肌细胞中存在的独特储存性Ca内流途径。这些研究表明,IA65是Orai亚型选择性药物转化与开发的一个范例。IA65激活CDI的能力表明,可以开发出能够增强Orai1介导的Ca内流但避免与持续Orai1激活相关的细胞毒性的药物。IA65和/或具有类似Orai1和CDI激活特性的未来类似物可能是特定疾病状态下重要生理过程的微调剂,如细胞迁移和免疫细胞功能。